207 related articles for article (PubMed ID: 34193287)
1. Determination of parasitic burden in the brain tissue of infected mice in acute toxoplasmosis after treatment by fluconazole combined with sulfadiazine and pyrimethamine.
Sina S; Mohammad JM; Reza S; Anita M; Soudabeh E; Hadi M
Eur J Med Res; 2021 Jun; 26(1):65. PubMed ID: 34193287
[TBL] [Abstract][Full Text] [Related]
2. Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model.
Martins-Duarte ÉS; de Souza W; Vommaro RC
Exp Parasitol; 2013 Mar; 133(3):294-9. PubMed ID: 23270807
[TBL] [Abstract][Full Text] [Related]
3. A clinical-parasitological monotherapy cure in the treatment of experimental infection by a highly virulent strain of Toxoplasma gondii.
de Diego JA; Penin P; Arribas JR; Vázquez E; Vázquez JJ
Folia Microbiol (Praha); 1996; 41(6):513-6. PubMed ID: 9131805
[TBL] [Abstract][Full Text] [Related]
4. Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.
Araujo FG; Suzuki Y; Remington JS
Eur J Clin Microbiol Infect Dis; 1996 May; 15(5):394-7. PubMed ID: 8793398
[TBL] [Abstract][Full Text] [Related]
5. Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis.
Dunay IR; Heimesaat MM; Bushrab FN; Müller RH; Stocker H; Arasteh K; Kurowski M; Fitzner R; Borner K; Liesenfeld O
Antimicrob Agents Chemother; 2004 Dec; 48(12):4848-54. PubMed ID: 15561866
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.
Romand S; Pudney M; Derouin F
Antimicrob Agents Chemother; 1993 Nov; 37(11):2371-8. PubMed ID: 8285620
[TBL] [Abstract][Full Text] [Related]
7. The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
Araujo FG; Lin T; Remington JS
J Infect Dis; 1993 Feb; 167(2):494-7. PubMed ID: 8421189
[TBL] [Abstract][Full Text] [Related]
8. Rifabutin is active in murine models of toxoplasmosis.
Araujo FG; Slifer T; Remington JS
Antimicrob Agents Chemother; 1994 Mar; 38(3):570-5. PubMed ID: 8203856
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled trial of pyrimethamine plus sulfadiazine versus trimethoprim plus sulfamethoxazole for treatment of toxoplasmic encephalitis in AIDS patients.
Kongsaengdao S; Samintarapanya K; Oranratnachai K; Prapakarn W; Apichartpiyakul C
J Int Assoc Physicians AIDS Care (Chic); 2008; 7(1):11-6. PubMed ID: 17517949
[TBL] [Abstract][Full Text] [Related]
10. Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group.
Podzamczer D; Miró JM; Ferrer E; Gatell JM; Ramón JM; Ribera E; Sirera G; Cruceta A; Knobel H; Domingo P; Polo R; Leyes M; Cosin J; Fariñas MC; Arrizabalaga J; Martínez-Lacasa J; Gudiol F
Eur J Clin Microbiol Infect Dis; 2000 Feb; 19(2):89-95. PubMed ID: 10746493
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of sulfadiazine and pyrimetamine for treatment of experimental toxoplasmosis with strains obtained from human cases of congenital disease in Brazil.
Silva LA; Fernandes MD; Machado AS; Reis-Cunha JL; Bartholomeu DC; Almeida Vitor RW
Exp Parasitol; 2019 Jul; 202():7-14. PubMed ID: 31077733
[TBL] [Abstract][Full Text] [Related]
12. Azithromycin reduces ocular infection during congenital transmission of toxoplasmosis in the Calomys callosus model.
Lopes CD; Silva NM; Ferro EA; Sousa RA; Firminot ML; Bernardes ES; Roque-Barreira MC; Pena JD
J Parasitol; 2009 Aug; 95(4):1005-10. PubMed ID: 20050006
[TBL] [Abstract][Full Text] [Related]
13. Sulfadiazine plasma concentrations in women with pregnancy-acquired compared to ocular toxoplasmosis under pyrimethamine and sulfadiazine therapy: a case-control study.
Reiter-Owona I; Hlobil H; Enders M; Klarmann-Schulz U; Gruetzmacher B; Rilling V; Hoerauf A; Garweg JG
Eur J Med Res; 2020 Nov; 25(1):59. PubMed ID: 33228795
[TBL] [Abstract][Full Text] [Related]
14. A study for precision diagnosing and treatment strategies in difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections.
Li Y; Zeng YM; Lu YQ; Qin YY; Chen YK
Medicine (Baltimore); 2020 May; 99(20):e20146. PubMed ID: 32443329
[TBL] [Abstract][Full Text] [Related]
15. Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis.
Derouin F; Almadany R; Chau F; Rouveix B; Pocidalo JJ
Antimicrob Agents Chemother; 1992 May; 36(5):997-1001. PubMed ID: 1324642
[TBL] [Abstract][Full Text] [Related]
16. In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice.
Piketty C; Derouin F; Rouveix B; Pocidalo JJ
Antimicrob Agents Chemother; 1990 Aug; 34(8):1467-72. PubMed ID: 2221854
[TBL] [Abstract][Full Text] [Related]
17. Folinic acid supplements to pyrimethamine-sulfadiazine for Toxoplasma encephalitis are associated with better outcome.
Van Delden C; Hirschel B
J Infect Dis; 1996 May; 173(5):1294-5. PubMed ID: 8627092
[No Abstract] [Full Text] [Related]
18. The timing of sulfadiazine therapy impacts the reactivation of latent Toxoplasma infection in IRF-8-/- mice.
Jost C; Reiter-Owona I; Liesenfeld O
Parasitol Res; 2007 Nov; 101(6):1603-9. PubMed ID: 17846793
[TBL] [Abstract][Full Text] [Related]
19. Determination of the inhibitory effect on Toxoplasma growth in the serum of AIDS patients during acute therapy for toxoplasmic encephalitis.
Derouin F; Gérard L; Farinotti R; Maslo C; Leport C
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep; 19(1):50-4. PubMed ID: 9732069
[TBL] [Abstract][Full Text] [Related]
20. Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine.
Schoondermark-van de Ven E; Galama J; Vree T; Camps W; Baars I; Eskes T; Meuwissen J; Melchers W
Antimicrob Agents Chemother; 1995 Jan; 39(1):137-44. PubMed ID: 7695295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
